Long-term administration of Alzheimer's drugs, clear differences in positions between Eisai and Lily
2024/7/31 14:33 JST (some excerpts)
Patients benefit from Eisai's Rekenbi administration for at least 3 years
Donanemab can be discontinued if amyloid is reduced to a minimum level - Lily
Eisai and Eli Lilly of the United States differ greatly on the basic question of whether treatment drugs should be administered to patients with Alzheimer's disease over a long period of time.
On the 30th, at the Alzheimer's Association International Conference 2024 being held in Philadelphia, USA, Eisai announced data suggesting that patients can benefit from “rekenbi (generic name lecanemab)” jointly developed with US Biogen for at least 3 years. Meanwhile, competitor Eli Lilly pointed out that if the toxic brain protein amyloid is reduced to a minimum level, administration can be stopped sooner than that for its donanemab.
Patients benefit from Eisai's Rekenbi administration for at least 3 years
Donanemab can be discontinued if amyloid is reduced to a minimum level - Lily
Eisai and Eli Lilly of the United States differ greatly on the basic question of whether treatment drugs should be administered to patients with Alzheimer's disease over a long period of time.
On the 30th, at the Alzheimer's Association International Conference 2024 being held in Philadelphia, USA, Eisai announced data suggesting that patients can benefit from “rekenbi (generic name lecanemab)” jointly developed with US Biogen for at least 3 years. Meanwhile, competitor Eli Lilly pointed out that if the toxic brain protein amyloid is reduced to a minimum level, administration can be stopped sooner than that for its donanemab.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
